Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Case ReportCase Studies

Development of a Premium Quality Plasma-derived IVIg (IQYMUNE®) Utilizing the Principles of Quality by Design—A Worked-through Case Study

Philippe Paolantonacci, Philippe Appourchaux, Béatrice Claudel, Monique Ollivier, Richard Dennett and Laurent Siret
PDA Journal of Pharmaceutical Science and Technology March 2018, 72 (2) 176-187; DOI: https://doi.org/10.5731/pdajpst.2016.007393
Philippe Paolantonacci
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Appourchaux
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Béatrice Claudel
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monique Ollivier
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Dennett
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Siret
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: siret@lfb.fr
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 72 no. 2 176-187
DOI 
https://doi.org/10.5731/pdajpst.2016.007393
PubMed 
29158287

Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Published online March 23, 2018.

Article Versions

  • previous version (November 20, 2017 - 18:35).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© PDA, Inc. 2018

Author Information

  1. Philippe Paolantonacci,
  2. Philippe Appourchaux,
  3. Béatrice Claudel,
  4. Monique Ollivier,
  5. Richard Dennett and
  6. Laurent Siret*
  1. Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, France †Voisin Consulting Life Sciences, Boulogne, France
  1. ↵* Corresponding Author: Laboratoire Français du Fractionnement et des Biotechnologies, 3 avenue des Tropiques, BP 40305, 91958 Courtaboeuf cedex, France; e-mail: siret{at}lfb.fr
View Full Text

Cited By...

  • 2 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study
    Eduardo Nobile‐Orazio, Sonia Pujol, Fabrice Kasiborski, Rabye Ouaja, Gilles Della Corte, Robert Bonek, Dario Cocito, Angelo Schenone
    Journal of the Peripheral Nervous System 2020 25 4
  • Application of a caprylate/chromatography purification process for production of a high potency rabies immune globulin from pooled human plasma
    Michelle Woznichak, Pete Vandeberg, Catherine Russ, Chad Talton, Jyoti Srivastava, Vik Arora, W. Keither Merritt, Marta Jose
    Journal of Immunological Methods 2021 499
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 72 (2)
PDA Journal of Pharmaceutical Science and Technology
Vol. 72, Issue 2
March/April 2018
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of a Premium Quality Plasma-derived IVIg (IQYMUNE®) Utilizing the Principles of Quality by Design—A Worked-through Case Study
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
17 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Development of a Premium Quality Plasma-derived IVIg (IQYMUNE®) Utilizing the Principles of Quality by Design—A Worked-through Case Study
Philippe Paolantonacci, Philippe Appourchaux, Béatrice Claudel, Monique Ollivier, Richard Dennett, Laurent Siret
PDA Journal of Pharmaceutical Science and Technology Mar 2018, 72 (2) 176-187; DOI: 10.5731/pdajpst.2016.007393

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of a Premium Quality Plasma-derived IVIg (IQYMUNE®) Utilizing the Principles of Quality by Design—A Worked-through Case Study
Philippe Paolantonacci, Philippe Appourchaux, Béatrice Claudel, Monique Ollivier, Richard Dennett, Laurent Siret
PDA Journal of Pharmaceutical Science and Technology Mar 2018, 72 (2) 176-187; DOI: 10.5731/pdajpst.2016.007393
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Stage 1: Product/Process Design—Quality Target Product Profile (QTPP)
    • Stage 2: Product Risk Analysis—Identification of Critical Quality Attributes (CQAs)
    • Stage 3: Process Risk Analysis—Identification of Critical Steps
    • Stage 4: Process Risk Mitigation, Robustness Studies—Critical Process Parameters (CPPs) With Proven Acceptable Ranges (PARs)
    • Stage 5: Control Strategy (CS)
    • Conclusion
    • Conflict of Interest Declaration
    • Acknowledgments
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Phase-Incremental Decision Trees for Multi-Phase Feature Selection and Interaction in Biologics Manufacturing
  • Practical Application of Setting up an Annual Contamination Control Strategy (CCS) Assessment
  • A Risk Assessment and Risk Based Approach Review of Pre-use/Post Sterilization Integrity Testing (PUPSIT)
Show more Case Studies

Similar Articles

Keywords

  • Quality by Design
  • polyvalent human normal immunoglobulins
  • intravenous immunoglobulins
  • IQYMUNE®
  • CLAIRYG®
  • quality risk management

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire